Amgen Inc
AMGN:NASDAQ
| Last | Change / % Change | Dividend Yield | Volume |
| 56.50 | 0.1800 0.32% | 0.00% | 5,893,725 |
Market data is delayed by at least 20 minutes.
Exclusive Features
When you open a Scottrade account, you will be able to trade, add stocks to a watch list, set alerts and get real-time quotes.
For full analysis details, Log In with Scottrade or you can:
Latest News Headlines for Amgen Inc
Amgen Set to Possibly Pullback after Yesterday's Rally of 0.32% (AMGN)
Amgen (NASDAQ:AMGN) traded in a range yesterday that spanned from a low of $56.05 to a high of $57.28. Yesterday, the shares gained 0.32%, which took the trading range above the 3-day high of $57.00 on volume of 5.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Upside Reversal for Amgen
Upside Reversal for Amgen
By Mike Paulenoff, www.MPTrader.com
an AdviceTrade.com publication
Today's sharp morning session upside reversal in Amgen (AMGN) is "threatening" to put in a key upside reversal day -- provided the stock closes above 57.14. So far today, the action has the right look and feel of a price structure that ended a correction -- in this case a sideways digestion period since Jan 4 -- ahead of a thrust into a new upleg.
Through 1278 SPX....
View more recent headlinesby Jack Steiman, www.SwingTradeOnline.com
an AdviceTrade.com publication
The market has been gravitating higher slowly but surely, no question. Over the past many weeks it had set up shop between the gap top low at 1262 and the 1278 as its high. A few tests down at 1262 looked like a breakdown was finally upon us, but that was not to be. There were many test back up to 1278, but failed as well, so it became a chess match between who would make the move first. The bulls pulled off the move today. It wasn't a shocking move higher as we're barely above 1278. Slightly less than half a percent above, but we are above, and that can't be denied by anyone. This opens the door to a move up to the top of the trend line at 1300 on the S&P; 500. That chart is there for your viewing this evening. It seems as if this market doesn't waste a point. Although, by no means a guarantee, if the trend line is open to approximately 1300 on the SPX, it seems as if it will find a way to make it there, even if it doesn't hold once it does get there.
Company Background
Amgen Inc. (Amgen) is an independent biotechnology medicines company. The Company discovers, develops, manufactures and markets medicines for grievous illnesses. It focuses on human therapeutics and concentrates on medicines based on advances in cellular and molecular biology. Its principal products include Aranesp (darbepoetin alfa) and EPOGEN (Epoetin alfa), erythropoietic-stimulating agents (ESAs) that stimulate the production of red blood cells; Neulasta (pegfilgrastim), a pegylated protein, based on the Filgrastim molecule, and NEUPOGEN (Filgrastim), a recombinant-methionyl human granulocyte colony-stimulating factor (G-CSF), both of which selectively stimulate the production of neutrophils (a type of white blood cell that helps the body fight infection), and Enbrel (etanercept), an inhibitor of tumor necrosis factor (TNF), a substance that plays a role in the body's response to inflammatory diseases.
Bid/Size -- / -- | Ask/Size -- / -- |
Price Open 56.05 | Previous Close 56.32 |
Day High 57.28 | Day Low 56.05 |
52wk High/Date 61.26 / 4/19/2010 | 52wk Low/Date 50.26 / 8/27/2010 |
Beta 0.47 | Market Capitalization 53B |
Shares Outstanding 945M | Volatility Avg 22.50 |
Avg Vol(10 day) 5M | P/E Ratio 12.2x |
EPS (TTM) 5 | Annualized Rate -- / -- |
Yield 0.00% | Dividend Announcement -- |
Ex-Date -- | Date of Record -- |
Payable 0.00 - -- | Payable Date -- |
Last Trade as of 1/14/2011 4:00 PM ET | |
Exclusive Content
When you open an account with Scottrade, you will get premium content on the News & Content page, including:
- Standard & Poor's News and Commentary
- Dow Jones News
- Briefing News and Commentary
- Market Edge On the Edge Commentary
For full analysis details, Log In with Scottrade or you can:
AMGN Amgen Inc vs. Peers
| Peers | |
AMGN Amgen Inc | 2.91% |
| JNJ Johnson & Johnson | 1.13% |
| HSP Hospira, Inc. | 1.08% |
| MRK Merck & Co., Inc. | -5.02% |
| ABT Abbott Laboratories | -2.13% |
AMGN Amgen Inc | 0.00% |
| JNJ Johnson & Johnson | 3.45% |
| HSP Hospira, Inc. | -- |
| MRK Merck & Co., Inc. | 4.44% |
| ABT Abbott Laboratories | 3.75% |
AMGN Amgen Inc | 0.32% |
| JNJ Johnson & Johnson | -0.57% |
| HSP Hospira, Inc. | 0.16% |
| MRK Merck & Co., Inc. | -1.33% |
| ABT Abbott Laboratories | -1.01% |